Home › Cancro del polmone non a piccole cellule › Pennsylvania › Reading
Studi clinici su Cancro del polmone non a piccole cellule a Reading, PA
9 studi su Cancro del polmone non a piccole cellule cercano partecipanti presso sedi a Reading e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
In reclutamentoFase 3
- Reading Hospital, West Reading · a 1 mi di distanza
- Ephrata Cancer Center, Ephrata · a 17 mi di distanza
- Sechler Family Cancer Center, Lebanon · a 26 mi di distanza
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
In reclutamentoFase 3
- Reading Hospital, West Reading · a 1 mi di distanza
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
In reclutamentoFase 2
- McGlinn Cancer Institute Reading Hospital, West Reading · a 1 mi di distanza
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
In reclutamentoFase 3
- Reading Hospital - McGlinn Cancer Institute, West Reading · a 1 mi di distanza
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
In reclutamentoFase 2
- Ephrata Cancer Center, Ephrata · a 17 mi di distanza
- Sechler Family Cancer Center, Lebanon · a 26 mi di distanza
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
In reclutamentoFase 2
- Ephrata Cancer Center, Ephrata · a 17 mi di distanza
- Sechler Family Cancer Center, Lebanon · a 26 mi di distanza
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
In reclutamentoFase 2
- Ephrata Cancer Center, Ephrata · a 17 mi di distanza
- Sechler Family Cancer Center, Lebanon · a 26 mi di distanza
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
In reclutamentoFase 2/3
- Ephrata Cancer Center, Ephrata · a 17 mi di distanza
- Sechler Family Cancer Center, Lebanon · a 26 mi di distanza
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
In reclutamentoStudio osservazionale
- Ephrata Cancer Center, Ephrata · a 17 mi di distanza
- Sechler Family Cancer Center, Lebanon · a 26 mi di distanza
Studi su Cancro del polmone non a piccole cellule in altre città
- Houston, TX145 studi
- New York City, NY120 studi
- Arlington, VA104 studi
- Nashville, TN97 studi
- Boston, MA90 studi
- Los Angeles, CA87 studi
- St. Louis, MO73 studi
- Chicago, IL61 studi
- Baltimore, MD60 studi
- San Antonio, TX59 studi
- Columbus, OH56 studi
- Washington, DC55 studi
Altri studi a Reading
- Cancro ai polmoni11 studi
- Leucemia mieloide acuta5 studi
- Cancro al seno5 studi
- Disturbi della sonnolenza eccessiva5 studi
- Cancro alla prostata4 studi
- Cancro (tutti i tipi)4 studi
- Cancro colorettale3 studi
- Narcolessia3 studi
- Disturbi del sonno3 studi
- Affaticamento3 studi
Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.